FDA research centre invests in biomarker discovery solution
29 October 2008Tweet
The National Center for Toxicological Research of the US Food and Drug Administration has signed up to use Genedata’s Expressionistbiomarker discovery platform.
Genedata Expressionist is a modular computational platform for biomarker discovery that integrates transcriptomics, proteomics and metabolomics data within a single enterprise software system.
With high-throughput data processing and automated workflows for quality assessment, as well as statistical analysis and interpretation tools, the platform provides a single point of access for all experimental data, including sample information, raw and pre-processed data, analysis results and documentation with reports.
Weida Tong, director of the Center for Toxicoinformatics at the US Food and Drug Administration (FDA), said, 'We have successfully applied Genedata Expressionist in a number of FDA projects, including the Critical Path project and the Liver Toxicity Knowledge Base (LTKB) project. Expressionist is an excellent system for monitoring the quality of gene expression data.'